Healthcare innovator to create 20 Northumberland jobs following inward manufacturing move
Healthcare firm Femeda has started its production of medical devices in Cramlington, which are used for the treatment of female urinary incontinence, after relocating its manufacturing lines from the United States to Northumberland a year ago.
The growing business, which already employs 12 people in the North East, will soon be recruiting for an additional 20 positions as the firm looks to scale considerably next year.
Needing to secure a scalable supply chain ahead of launching its new pelvic health product in early 2018, the business CEO Andrew Tasker cited the region as an ideal location to innovate in the sector.
He explained: “It’s great to be able to establish our in-house manufacturing capabilities and our ground-breaking technology in the North East.
“Our team are looking forward to launching our life-changing technology Pelviva® to women suffering from incontinence early next year.”
With 698 million women worldwide affected by incontinence, and a compound annual growth rate of 6%, the company has forecast significant market penetration for Pelviva® which uses reactive pulse technology to strengthen weak pelvic floor muscles, the underlying cause of urinary incontinence.
Andrew has over 30 years’ experience in consumer healthcare, medical devices and pharmaceuticals including working for Procter & Gamble, Boots, Bausch + Lomb and in MD roles at Pfizer Consumer Healthcare and Mentholatum.
His experience has seen him work across multiple health care sectors in the UK, Europe and Middle East Africa, launching multiple new technologies and innovations.
“We chose Cramlington for its strong heritage and reputation in healthcare and medical manufacturing,” added Andrew.
“We were quickly able to develop a highly experienced team to start our initial manufacturing. We plan to continue to expand the site as we initiate our global launch plan.”
Access free online guidance for North East businesses in the Growth Hub North East's COVID-19 toolkit →